CBD vs CBG vs CBN: Key Differences Explained

CBD vs CBG vs CBN - Introduction

CBD vs CBG vs CBN: what is the difference? Cannabidiol, cannabigerol and cannabinol are distinct cannabinoids associated with the cannabis plant. CBD has a substantially larger research base, while human research on CBG and CBN is still developing.

You will often see CBD marketed for general wellness, CBG for focus and CBN for sleep. Those descriptions are marketing shortcuts, not a dependable guide to what a finished product will do.

This guide explains the differences, separates research findings from product claims, and highlights what to check when comparing cannabinoid products in Malta.

CBD, CBG and CBN at a glance

Cannabinoid	Full name	Research position	What not to assume
CBD	Cannabidiol	The most extensively studied of these three; a prescription CBD medicine has specific authorised uses.	That ordinary retail products have the same evidence, formulation or effects as a medicine.
CBG	Cannabigerol	Much of the research is preclinical, with limited early human studies.	That it reliably improves concentration, productivity or digestive health.
CBN	Cannabinol	Human sleep studies are emerging, with mixed results across different measures.	That it is a proven insomnia treatment or guarantees a better night's sleep.

What are cannabinoids?

Cannabinoids are a group of compounds that include substances produced by the body and compounds associated with the cannabis plant. The body's endocannabinoid system participates in several physiological processes, but describing a product as “supporting the ECS” does not establish a particular health benefit.

CBD, CBG and CBN have different chemical structures and biological actions. Their effects cannot be predicted simply by grouping them together as hemp-derived ingredients.

CBD: a larger research base, with important distinctions

CBD is better studied than CBG or CBN. In the EU, the prescription medicine Epidyolex contains cannabidiol and is authorised for certain seizure disorders under specific treatment conditions.

That authorisation applies to the medicine and its approved uses. It does not mean that a retail CBD oil, cream, capsule or vape is approved to treat anxiety, pain, inflammation or sleep problems.

When reading a CBD study, check what was actually investigated: the formulation, amount, route of administration, participants and outcome. A result from a particular oral preparation cannot automatically be applied to a topical product or an inhaled formulation.

Practical takeaway: compare the actual product information rather than treating “contains CBD” as proof of a benefit.

CBG: why the “mother cannabinoid” description needs context

CBG stands for cannabigerol. Its acidic precursor, CBGA, is involved in the plant pathways that produce several other cannabinoid acids. Calling CBG itself a “stem cell cannabinoid” oversimplifies this chemistry.

A small placebo-controlled crossover study published in 2024 involved 34 healthy adults. It reported changes in some anxiety, stress and verbal-memory measures after CBG. The study was short-term and conducted remotely, so its findings need replication and do not establish treatment benefits or long-term safety.

Laboratory and animal research also explores other possible actions. Those findings should not be presented as demonstrated digestive, neurological or anti-inflammatory benefits in customers.

Practical takeaway: “daytime” or “focus” on a product name does not mean that CBG has been proven to improve everyday concentration.

CBN: what does the sleep research show?

CBN stands for cannabinol. It can form as THC undergoes chemical changes during ageing and exposure to environmental conditions. This does not tell you how the CBN in a commercial product was manufactured; sourcing and production information still matter.

CBN is frequently marketed in evening products, but the human evidence is not a simple story of “CBN makes you sleep.”

A short placebo-controlled trial found improvements in nighttime awakenings and overall sleep disturbance, but its primary sleep-quality outcome did not reach statistical significance. Adding CBD did not improve the treatment effects in that study.
A small 2026 trial involving 20 adults with insomnia did not find a significant improvement in its primary measure of wakefulness after initially falling asleep.

These studies used specific oral preparations and study conditions. They do not establish that a CBN vape, oil or multi-ingredient retail blend will produce the same results.

Practical takeaway: check the full formula. If a product also contains melatonin or other active ingredients, you cannot attribute its effects to CBN alone.

Are CBD, CBG and CBN non-intoxicating?

CBD and CBG are commonly described as non-intoxicating, meaning they are not generally associated with the characteristic THC high. That does not mean they are biologically inactive, free of side effects or suitable for everyone.

CBN should not be given an unconditional “will not impair you” label. Its human evidence is more limited, and the amount, formulation and other ingredients matter.

A low THC percentage alone does not guarantee that a finished product cannot cause drowsiness or impairment. Do not drive or operate machinery if you feel affected.

Are cannabinoid blends better than single ingredients?

The “entourage effect” describes proposed interactions between cannabis constituents. It is not proof that every full-spectrum product is more effective than an isolate, or that adding CBD, CBG and CBN together produces a better result.

More ingredients also make it harder to identify which component is responsible for an effect or unwanted reaction. Compare the evidence for the actual formulation wherever available.

You do not need all three cannabinoids simply because they appear together in a product range.

How to compare cannabinoid product labels

Identify the intended use. An oral product, cosmetic and inhalation product are not interchangeable. Follow the labelled use; do not put oral oils into a vaporizer.
Look for individual cannabinoid amounts. A total extract amount does not necessarily tell you how much CBD, CBG or CBN is present.
Compare like-for-like units. Check whether the label gives milligrams per bottle, millilitre, capsule or other unit. Percentages alone can be difficult to compare.
Read every ingredient. Carrier oils, fragrances, melatonin and other ingredients may affect suitability and the interpretation of product claims.
Check batch documentation. A relevant certificate of analysis should identify the sample, batch and tests performed. A cannabinoid-potency result is not automatically a pesticide, solvent or heavy-metal test.
Check THC information carefully. “Not detected” refers to the test's detection or reporting limit; it is not an absolute guarantee of zero.

A laboratory report can help verify particular measurements. It does not, by itself, prove clinical effectiveness or establish that the product is authorised for every intended use.

Safety: what does the latest European guidance say?

“Natural” and “non-intoxicating” do not establish safety. CBD can interact with medicines, and important uncertainties remain for long-term use and for less-studied cannabinoids.

In February 2026, EFSA published a provisional safe intake level for narrowly specified CBD food-supplement formulations. Its assessment applies only under defined purity and production conditions, and does not establish safety for people under 25, pregnant or breastfeeding people, or those taking medication.

This assessment is not a general dosing recommendation, an approval of every CBD product, or evidence about the safety of vaping. If you take medicines or have a health condition, ask a pharmacist or clinician about suitability. Persistent sleep, pain or anxiety symptoms deserve appropriate assessment.

CBD, CBG and CBN in Malta and the EU

There is no single “under 0.2% THC means legal everywhere” rule covering all finished cannabinoid products. Product category, composition, intended use, claims and destination all matter.

For foods and supplements, EU novel-food requirements are relevant to added cannabinoids and cannabinoid-rich extracts. Where a product is a novel food, the applicable authorisation requirements must be satisfied before it is marketed as food. Cosmetics, medicines and inhalation products have different requirements.

An EFSA safety assessment is not itself a European Commission market authorisation. Equally, being offered for sale in one country does not establish that a product may be sold or shipped for the same use in every other country.

For Malta-specific background, see our cannabis information page. Check the rules relevant to the exact product and destination rather than relying on a THC percentage alone.

Explore product information by cannabinoid

Use the collections below to compare labelled ingredients, formats and available documentation. Inclusion in a collection is not evidence that a product treats a particular condition.

If a label or ingredient list is unclear, contact Cannabis Clinics Malta with the product name. We can help clarify product information and available documentation; individual medical advice belongs with a qualified healthcare professional.